

**Title:** Antidepressant efficacy of administering repetitive transcranial magnetic stimulation (rTMS) concurrently with psychological tasks or interventions:  
a scoping review and meta-analysis

Cristian G. Giron<sup>1,✉</sup>, Alvin H.P. Tang<sup>2</sup>, Minxia Jin<sup>2,3</sup>, Georg S. Kranz<sup>2,4,✉</sup>

<sup>1</sup>Department of Psychology, The University of Hong Kong, Hong Kong SAR, China

<sup>2</sup>Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China

<sup>3</sup>Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, China

<sup>4</sup>Mental Health Research Center (MHRC), The Hong Kong Polytechnic University, Hong Kong

✉ Corresponding authors: [giron@hku.hk](mailto:giron@hku.hk), [georg.kranz@polyu.edu.hk](mailto:georg.kranz@polyu.edu.hk)

Word count	
Abstract	247
Main text	4186
References	57
Tables: 1; Figures: 4	

**Correspondence to:**

Mr. Cristian G. Giron

Department of Psychology, The University of Hong Kong

Hong Kong SAR, China.

Tel: 852-3917-8226

Email: [giron@hku.hk](mailto:giron@hku.hk)

Dr. Georg S. Kranz

Department of Rehabilitation Sciences, The Hong Kong Polytechnic University

Hong Kong SAR, China.

Tel: 852-2766-4838 Fax: 852-2330-8656

Email: [georg.kranz@polyu.edu.hk](mailto:georg.kranz@polyu.edu.hk)

## ABSTRACT

Current approaches to optimize the efficacy of repetitive transcranial magnetic stimulation (rTMS) for depressive symptoms focus on personalizing targets and parameters. But what should occur during these three-to-forty-minute sessions remains under-investigated. Specific concerns include evidence suggesting brain state modulates the brain's response to stimulation, and the potential to boost antidepressant efficacy by administering rTMS concurrently with psychological methods. Thus, conducted a scoping review and meta-analysis, per PRISMA-ScR guidelines, to pool studies that administered rTMS during psychological tasks or interventions. PubMed and Web of Science databases were searched from inception to 10 July 2024. Inclusion criteria: neuropsychiatric patients underwent rTMS; studies assessed depressive symptom severity; psychological tasks or interventions were administered during rTMS, or intentionally did not include a wash-out period. Of 8442 hits, 20 studies combined rTMS with aerobic exercise, bright light therapy, cognitive training or reactivation, psychotherapy, sleep deprivation, or a psychophysical task. Meta-analyses with random effects models pooled the efficacy of these combinations, based on change scores on depressive severity scales. The effect size was large and therapeutic for uncontrolled pretest-posttest comparisons (17 studies, 20 datasets,  $g=-1.91$ ,  $SE=0.45$ ,  $95\%CI= -2.80$  to  $-1.03$ ,  $p<0.01$ ); medium when studies compared active combinations with sham rTMS plus active psychological methods (8 studies,  $g=-0.55$ ,  $SE=0.14$ ,  $95\%CI= -0.82$  to  $-0.28$ ,  $p<0.01$ ); and non-significant when active combinations were compared with active rTMS plus sham psychological methods (4 studies,  $p= 0.96$ ). These findings suggest that the antidepressant efficacy of combining rTMS with psychological methods is promising, but not an improvement over rTMS alone.

**Keywords:** brain state, depression, meta-analysis, psychological interventions, rTMS, transcranial magnetic stimulation

## Introduction

Repetitive transcranial magnetic stimulation (rTMS) is a multi-tool for clinical practice and psychological research, with recommended applications across neuropsychiatric conditions (1). As an antidepressant, the efficacy of rTMS is supported by meta-analyses for major depressive disorder (MDD; (2)), and across neuropsychiatric conditions when applied over the left dorsolateral prefrontal cortex (3). Strategies to improve the efficacy and consistency of rTMS protocols focus on personalizing stimulation targets or parameters that maximize the dose of stimulation (4, 5). But what should occur during treatment sessions has received much less attention. What patients do during sessions is typically not reported, and advice is not provided by expert guidelines (1) or cannot be established due to a lack of evidence (6). When details are reported, patients are instructed to relax, e.g., “During 10 Hz rTMS or iTBS sessions, participants were instructed to keep their eyes open and relax” (7). But expecting patients with depressive syndromes to consistently follow these instructions is problematic: internalizing disorders, such as depressive disorders, are characterized by emotional and cognitive dyscontrol linked to abnormal brain activity and connectivity (8, 9). Since distinct behaviors and thoughts correspond to different brain states (i.e., activity and connectivity), and as different brain states may underlie receptivity to stimulation, it has been suggested that patients' actions and thoughts during stimulation contribute to the highly variable outcomes of rTMS (10-12). Such heterogeneity poses a significant challenge for antidepressant rTMS therapies. For instance, a meta-analysis of gold-standard trials applying rTMS to the left DLPFC found a large effect size but also substantial heterogeneity, indicated by a Higgin’s  $I^2$  of 86% (3). Further, inconsistent changes in brain hemodynamics are observed in both the targeted prefrontal region and remote areas during and after rTMS (13).

### *Evidence for the ‘brain state’ hypothesis of rTMS*

The potential for concurrent psychological tasks or interventions to alter the brain's response to rTMS, potentially controlling for brain state, is of great interest to clinicians and researchers. In reviews focusing on the cognitive neuroscience literature, Silvanto and colleagues suggest that TMS does not broadly excite, inhibit, or induce “virtual lesions” of targeted brain regions (12, 14). Instead, neuronal pools within these regions respond distinctly to stimulation, depending on their activity during stimulation. Similar reasoning has driven experiments to explore whether behavior during rTMS modulates brain responses in healthy participants. Neuroimaging studies show that the after-effects of high-frequency and high-intensity rTMS over the left dorsal premotor cortex are excitatory when the left hand is actively gripping during stimulation, but inhibitory when the left hand is at rest (15). Similar effects were observed using continuous and intermittent theta burst stimulation protocols (16). In another study, Luber and colleagues (17) paired audio-visual stimuli with single pulses in a classical conditioning task. The presentation of conditioned stimuli, but not unconditioned stimuli, before TMS attenuated motor-evoked potentials. More recently, a study interleaving TMS-fMRI found varied blood-oxygenation changes in response to TMS depending on whether healthy participants were at rest or performing the n-back task (18). These neuroimaging studies with healthy participants support the hypothesis that brain state at the time of TMS modulates the brain response to stimulation. However, behavioral studies do not support this hypothesis (19-21). To wit, behavioral after-effects following high frequency rTMS of the left dorsolateral prefrontal cortex (DLPFC) are not

modulated when healthy participants viewed positive compared to neutral affect-inducing images during stimulation (19), nor when stimulation is delivered during a working memory task compared to rTMS alone (20). However, these behavioral studies assessed after-effects with task performance or self-reported mood items that may not be sufficiently sensitive. Indeed, meta-analyses of studies with healthy participants report that rTMS alone has null or little effects on these behavioral measures (22, 23).

### *Previous reviews or perspectives on brain states and rTMS*

The evidence supports the hypothesis that rTMS after-effects can be influenced by participants' thoughts or actions during stimulation. This possibility has attracted significant interest from researchers and clinicians, leading to several reviews and perspectives on the topic (10, 11, 24-28). However, these have been non-systematic narrative reviews or overviews (10, 11, 24, 26, 27), did not examine treatment efficacy (26), or did not consider on the timing of the combined interventions (24, 25, 27, 28). We determined a scoping review was necessary to charter this literature and estimate efficacy, as we expected the literature to be highly heterogeneous inherent of rTMS research (2, 3), compounded by the variability of psychological tasks, interventions, and their timing with rTMS. To our knowledge, this is the first systematic effort to chart and conduct a meta-analysis on this research question. We aim to ground these findings by comparing efficacy estimates with published meta-analyses on the efficacy of rTMS alone and conduct power analyses to guide future research.

### *Objectives*

This scoping review systematically charts and meta-analyzes literature on the antidepressant efficacy of rTMS administered during or immediately after psychological tasks and interventions – putatively, rTMS with brain state manipulated. We included studies that combined these methods to treat any neuropsychiatric condition and reported effects on depression severity. Findings are discussed to inform combination designs for clinical and experimental research. The specific research objectives are as follow:

1. To investigate whether the antidepressant effects of rTMS are modulated (i.e., identify synergistic or antagonistic effects) by combination with psychological tasks and interventions.
2. Charter the literature relevant to future clinical and research paradigms integrating clinical rTMS protocols with psychological methods

### **Methods**

This scoping review complies with the reporting guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) (29). Its protocol was registered with the Open Science Framework on 25 June 2022 (<https://osf.io/n8hw3>).

### *Eligibility criteria*

The PICO model summarizing inclusion criteria is as follows:

- **Patient:** Human neuropsychiatric patients with depressive symptoms. Treated patients do not need to have a depressive disorder as a primary diagnosis. For example, if treated patients are diagnosed with post-traumatic stress disorder or a pain disorder, the study can be included if depression severity was assessed.
- **Intervention:** Non-pharmacological intervention overlaps with sessions of rTMS. Chronotherapies can be included if wash-out periods are not used (e.g., patients are sleep deprived during days where rTMS is administered). Combined neuromodulation or open- and closed-loop designs are excluded, as this literature is reviewed elsewhere. Studies are also excluded if only pharmacotherapy is combined with rTMS.
- **Comparison:** No restriction.
- **Outcome:** Study reports depression severity such as with the Hamilton Depression Rating Scale, visual analogue scales, or assessments by trained clinicians

Excluded criteria were: 1) rTMS was administered alone; 2) timing of treatments were not concurrent with rTMS; 3) combined rTMS with pharmacotherapy only; 4) combined rTMS with other neuromodulatory devices (e.g., transcranial electric stimulation), or utilized an open- or closed-loop design without a psychological task or intervention.

### *Information sources and search strategy*

The search was performed using broad terms for rTMS and depression in the PubMed database until 5 May 2022 (YTC, HYCC, SWC, YYC) and updated until 10 July 2024 to also include Web of Science database (CGG, AHPT, MJ). Search queries used for each database are shown in **Supplementary Table S1**. Search results were exported into EndNote 20 to facilitate screening. This was done independently by separate reviewer teams (YTC, HYCC and SWC, YYC), then updated by a separate team (CGG and AHPT, MJ). Reference list of relevant reviews and included studies were also screened. We anticipated screening would require multiple teams since the search queries and inclusion criteria were intentionally broad. Furthermore, reporting what patients do during rTMS sessions is unstandardized in this literature. Thus, many studies were expected to need careful full-text screening to confirm whether psychological tasks or interventions were combined with rTMS, and if so, whether they were concurrent.

### *Study selection and data chartering*

Reviewers first screened by title and abstract independently, then discussed and merged these screening results. Full-text retrieval and screening was then conducted by the same independent teams. Disagreements on study selection were resolved by discussion and consensus with GSK. No automation tools were used for full-text screening. A customized Excel spreadsheet was developed for data chartering by CGG (items are described in the next section). Once full-text screening was completed, data was extracted by CGG, YTC, HYCC, SWC, and YYC, then verified by MJ and AHPT. Any disagreements were resolved through discussion with GSK.

### *Extracted data*

The following items were extracted using a customized Excel spreadsheet: participant characteristics for each treatment group (diagnoses and diagnostic method; age; sex ratio); rTMS protocol (target site, pulse pattern and intensity, number of sessions); psychological task or intervention; timing of treatments; measurements of antidepressant outcome; reported results of statistical comparisons; estimated effect sizes for within-subjects and between-subjects comparisons for each study. If these data were visually presented but not numerically available, we used WebPlotDigitizer to extract numerical values (<https://automeris.io/WebPlotDigitizer/>, last accessed 23 June 2023). If needed efficacy data was not obtainable in the full-text or supplementary materials of a study, we contacted corresponding authors of a study via.

### *Groups and Comparisons*

To assess antidepressant efficacy, change scores were calculated for each group across treatment timepoint by subtracting baseline scores from endpoint scores on standardized clinical scales, such as the Hamilton Depression Rating Scale (HDRS). These change scores were then pooled with respect to comparison. Effect sizes were estimated for within-group comparisons (posttest minus pretest) and controlled comparisons (change scores of the active intervention minus control condition). We estimated separate meta-analytic effect sizes for the following comparisons, where PSYC refers to psychological task or intervention:

- Uncontrolled: [active rTMS + active PSYC] endpoint versus baseline scores;
- Controlled: [active rTMS + active PSYC] versus [active rTMS + sham PSYC];
- Controlled: [active rTMS + active PSYC] versus [sham rTMS + active PSYC];
- Controlled: [active rTMS + active PSYC] versus [sham rTMS + sham PSYC].

These comparisons are necessary tests for the hypothesis that combining treatments alters efficacy. For example, a combination of methods can be synergistic or antagonistic (i.e., a negative interaction effect). It is essential to consider controls for both rTMS and PSYC to make causal claims about altered efficacy following their combination.

For studies where statistical comparisons were not reported (e.g., case studies), post-treatment response or remission outcomes were extracted to estimate the antidepressant efficacy. Such studies were not included in any meta-analysis.

### *Effect sizes based on change-scores of within-group and between-group comparisons*

To compute effect sizes, we used custom scripts written in Python (version 3.11.5) with NumPy and panda libraries in a Jupyter Notebook environment. We computed standardized mean differences of change scores for individual study comparisons. Details of relevant algorithms (30, 31) and pseudocode is provided in **Supplementary Text 1**.

### *Meta-analysis and tests of heterogeneity*

Meta-analyses were conducted when at least three included studies conducted similar comparisons. We used the *metafor* package (32) in R version 4.3.3 (33) to conduct the meta-

analyses and meta-regressions, to assess publication and sensitivity bias, and to conduct subgroup analyses described below. Random-effects models were used for all comparisons to account for predicted variability among study effects. The Restricted Maximum Likelihood (REML) method was used to estimate the between-study variance.

To assess heterogeneity, we used Cochran's Q test and Higgin's I<sup>2</sup> statistic. A significant Q test indicates the presence of heterogeneity among study effects beyond sampling error. The I<sup>2</sup> statistic is used to estimate the proportion of total variation due to heterogeneity rather than sampling error: I<sup>2</sup> values below 30% indicate low heterogeneity, between 30-60% indicate moderate heterogeneity, values above 60% indicate substantial heterogeneity (30).

#### *Publication and sensitivity bias analyses*

Publication bias was assessed using funnel plots and Egger's regression intercept test in meta-analysis with ten or more studies due to concerns about insufficient power (34). Leave-one-out cross-validation sensitivity tests were conducted to identify whether any single study disproportionately influences meta-analytic results. To wit, we iteratively excluded one study at a time, re-ran the meta-analysis using *metafor* in R, and observed how the results changed with the exclusion of the given study. To assess the robustness of each meta-analytic estimate, we report: the range of Hedges' g's observed; highlight whether the direction of effect changes; and whether the meta-analytic estimate remains significant.

#### *Meta-regression*

To assess potential moderators, we conducted meta-regressions for meta-analytic estimates consisting of ten or more studies (30). The assessed moderators were sex ratios (number of male patients divided by number of female patients in a sample), mean age of a sample, and whether the psychological task or intervention was a supported intervention for depressive symptom (e.g., psychotherapies) or not (e.g., psychophysical tasks).

#### *Secondary meta-analysis*

Meta-analyses were repeated to include only studies targeting the left dorsolateral prefrontal cortex (left DLPFC) and recruited patients with depressive disorders. This would allow us to compare meta-analytic findings with a recent cross-diagnostic meta-analysis that synthesized the effects of active rTMS relative to sham rTMS (3). This would allow us to compare combination treatment efficacy with rTMS alone.

#### *Monte-Carlo simulation-based power analysis*


To estimate the sample size needed to obtain sufficient power ( $\beta=0.80$ , given  $\alpha=0.05$ ) to investigate the hypothesis that combining rTMS with PSYC is a superior treatment (compared to sham conditions), we used the results of representative studies in simulation-based power analysis. Methods are described in **Supplementary Text 4**.

## **Results**



## Selection and sources of evidence

8442 records were identified in PubMed, Web of Science, and the reference lists of included studies and relevant reviews. The summary flow diagram is shown in **Figure 1**, and the PRISMA-ScR checklist is provided in **Supplementary Table S2**. References and reasons for 183 excluded studies that underwent full-text screening are shown in **Supplementary Table S3**. Twenty studies were eligible for inclusion.




**Figure 1.** Summary flow-diagram of literature screening.

## Characteristics of included studies

The literature on modulating antidepressant outcomes of rTMS or psychological interventions by their combination comprised twenty studies (35-54), chartered in **Table 1**. Eleven studies conducted between-group comparisons (35, 40-45, 47, 49, 50, 52), six reported

within-group comparison only (36, 38, 39, 46, 48, 51), and three were a case study or series (37, 53, 54)

Thirteen of twenty studies recruited patients diagnosed with major depressive disorder (MDD), post-stroke depression, or persistent depressive disorder (dysthymia) (35, 38, 39, 41, 43-46, 48, 50, 51, 53, 54):. Six other studies recruited patients with other neuropsychiatric conditions with comorbid depressive symptoms, namely, Alzheimer’s disease (36), cocaine use disorder (47), and post-traumatic stress disorder (42, 49, 52). MDD patients in eight included studies were treatment resistant (35, 38, 39, 43, 46, 48, 51, 54), with one study also recruiting patients with treatment resistance in bipolar disorder (35). Schedules of psychological methods combined with rTMS is illustrated in **Figure 2**.



**Figure 2.** Boxes indicate schedules of psychological interventions that have been attempted before or during sessions of rTMS. For example, the first box below “rTMS” indicates complete concurrence; the next box indicates interventions that start before rTMS then continue through an rTMS session. Box dimensions are not scaled to durations or any property of the interventions (e.g., dose). \*Cognitive training was interleaved with rTMS trains. Abbreviations: rTMS, repetitive transcranial magnetic stimulation; ACC, anterior cingulate cortex.

The DLPFC was a prime target, with seventeen of twenty studies targeting this region (35, 36, 38-52): sixteen targeted the left DLPFC (35, 36, 38-48, 50, 51, 53), two studies targeted the right DLPFC (49, 52), and four studies targeted bilateral DLPFC (36, 38, 39, 42).

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Barbini et al., 2021 (35)	<p><b>Diagnosis:</b> MDD (DSM-5) BD (MINI)</p> <p><b>[rTMS + BLT] n (Male/Female):</b> 40 (13/27) <b>Age (mean ± SD):</b> 58.8 ± 10.47</p> <p><b>[rTMS alone] n (Male/Female):</b> 40 (28/12) <b>Age:</b> 57.72 ± 9.89</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> n.m.</p> <p><b>Total no. of rTMS sessions:</b> 15</p>	Bright light therapy (BLT)	30 min upon awakening at an individualized time, followed by rTMS at noon	<p>HDRS</p> <p>[rTMS + BLT] vs [rTMS alone]: Hedges' <math>g = -1.018</math> (SE=0.236), ↑</p> <p>[rTMS + BLT]: <math>g = -0.382</math> (SE=0.209), ↑*</p>
Bentwich et al., 2011 (36)	<p><b>Diagnosis:</b> Probable early or moderate Alzheimer's Disease (DSM-IV) 6/8 with comorbidity of depression (n.m.)</p> <p><b>[rTMS + COG] n:</b> 8 (6/2) <b>Age:</b> 75.4 ± 4.4</p>	<p><b>Target sites:</b> - Broca &amp; Wernicke - right DLPFC &amp; left DLPFC - R-pSAC &amp; L-pSAC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> Broca, right DLPFC &amp; left DLPFC: 90% MT Wernicke, R-pSAC &amp; L-pSAC: 110% MT</p> <p><b>Pulses per session:</b> 1,200</p> <p><b>Total no. of rTMS sessions:</b> 30 sessions (at 5 per week for 6 weeks) + 24 maintenance sessions (2 per week for 3 months)</p>	Cognitive training	Interleaved cognitive training between rTMS trains	<p>HDRS</p> <p>[rTMS + COG] after 30 sessions: <math>g = -0.999</math> (SE=0.401); n.s.*</p> <p>[rTMS + COG] after 30 sessions plus 24 maintenance (54 total sessions): <math>g = -0.330</math> (SE= 0.340); n.s.*</p>

Study	Sample Information		rTMS Protocol		Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Caloc'h et al., 2023 (37)	<p><b>Diagnosis:</b> post-TBI syndrome (n.m.)</p> <p><b>Age:</b> 48 (1/0)</p>		<p><b>Target sites:</b> right and left DLPFC, Broca's and Wernicke's language areas, right and left posterior parietal areas</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 100% RMT</p> <p><b>Pulses per session:</b> 2400</p> <p><b>Total no. of rTMS sessions:</b> 30</p>		computerized cognitive training	Interleaved cognitive training between rTMS trains	<p>Hospital Anxiety and Depression Scale (HADS)</p> <p>Pre to post intervention score=18/42 to 30/42</p>
Cavallero et al., 2021 (38)	<p><b>Group in 1<sup>st</sup> site n:</b> 16 (3/13)</p>	<p><b>Diagnosis:</b> Non-psychotic MDD (n.m.)</p> <p><b>Age:</b> 48.4 ± 15.2</p>	<p><b>Target site:</b> Left DLPFC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> min: 3,000</p>	<p><b>Total no. of rTMS sessions:</b> Average: 35 ± 7.7</p>	Mindfulness-based cognitive therapy (MBCT): Audio-guided meditation exercises	During rTMS	<p>IDS-SR</p> <p>[rTMS + MBCT]: g=-2.050 (SE= 0.421), ↑*</p>
	<p><b>Group in 2<sup>nd</sup> site n:</b> 11 (5/6)</p>		<p><b>Target sites:</b> right DLPFC → left DLPFC</p> <p><b>Frequency:</b> 1 Hz (right DLPFC) → 20 Hz (left DLPFC)</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> 360 (right DLPFC) → 1,200 (left DLPFC)</p>				

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Donse et al., 2018 (39)	<p><b>[HF rTMS + psychotherapy] n:</b> 74 (n.m.)</p> <p><b>[LF rTMS + psychotherapy] n:</b> 115 (n.m.)</p>	<p><b>Diagnosis:</b> Non-psychotic MDD / Dysthymia (MINI / DSM-IV / DSM-5)</p> <p><b>Age:</b> 43.2 ± 12.9</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>rTMS parameters:</b> 10 Hz</p> <p><b>Intensity:</b> 110-120% RMT</p> <p><b>Pulse per session:</b> 1,500</p> <p><b>Duration per session:</b> 45 mins (rTMS being 20 min, with psychotherapy continuing until 45 minutes)</p> <p><b>Total no. of rTMS sessions:</b> Average: 20.9 (SD=7.5) Range: 10-50 sessions</p> <p><b>Target site:</b> right DLPFC → left DLPFC</p> <p><b>Frequency:</b> LF protocol (shorter duration of 1,000 pulses per session) → HF protocol at full length</p>	<p>Psychotherapy: Consisted of evidence-based methods, e.g., CBT, schema therapy, eye movement desensitization and reprocessing, schema therapy</p>	<p>During rTMS &amp; continued after rTMS for 25 mins</p> <p>BDI</p> <p>[HF rTMS + psychotherapy]: <math>g = -1.716</math> (SE=0.182), ↑*</p> <p>[LF rTMS + psychotherapy]: <math>g = -1.428</math> (SE=0.132), ↑*</p>

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Duan et al., 2023 (40)	<p><b>Diagnosis:</b> Post-stroke depression (DSM-5)</p> <p><b>[active rTMS + active adjunct] n:</b> 23 (19/4) <b>Age:</b> 58.3 ± 13.1</p> <p><b>[sham rTMS + active adjunct] n:</b> 24 (20/4) <b>Age:</b> 53.6 ± 13.0</p> <p><b>[sham rTMS + sham adjunct] n:</b> 24 (19/5) <b>Age:</b> 54.42 ± 14.27</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 80% MT</p> <p><b>Pulses per session:</b> 1,400</p> <p><b>Total no. of rTMS sessions:</b> 20</p>	Mindfulness-Based Stress Reduction (MBSR)	<p>Mindfulness guided audio during rTMS.</p> <p>Other exercises of MBSR conducted separately from rTMS sessions</p>	<p>HDRS</p> <p>[active rTMS + MBSR] vs [sham rTMS + MBSR]: g=-0.120 (SE=0.287), ↑</p> <p>[active rTMS + MBSR] vs [sham rTMS + general psychological care]: g= -0.213 (SE=0.288), ↑</p> <p>[active rTMS + MBSR]: g=-0.382 (SE=0.209), ↑*</p>
Eichhammer et al., 2002 (41)	<p><b>Diagnosis:</b> MDD or BD (DSM-IV)</p> <p><b>[active rTMS + PSD] n:</b> 10 (4/6) <b>Age:</b> 44.9 ± 12.3</p> <p><b>[sham rTMS + PSD] n:</b> 10 (1/9) <b>Age:</b> 48.5 ± 11.6</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> n.m.</p> <p><b>Intensity:</b> 80% MT</p> <p><b>Pulses per session:</b> 1,000</p> <p><b>Total no. of rTMS sessions:</b> 4</p>	partial sleep deprivation (PSD)	PSD rTMS: the night before	<p>HDRS</p> <p>[active rTMS + PSD] vs [sham rTMS + PSD]: day 1 g=-0.177 (SE=0.429), n.s.; Day 2-4: ↑</p> <p>[active rTMS + PSD]: day 1 g=-3.064 (SE=0.744), ↑*</p>

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Fryml et al., 2019 (42)	<p><b>Diagnosis:</b> PTSD (DSM-5)</p> <p><b>[active rTMS + PE] n:</b> 5 (5/0) <b>Age:</b> 27 ± 2.1</p> <p><b>[sham rTMS + PE] n:</b> 3 (2/1) <b>Age:</b> 30 ± 2.6</p>	<p><b>Target site:</b> Left DLPFC or right DLPFC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% MT</p> <p><b>Pulses per session:</b> 6,000</p> <p><b>Total no. of rTMS sessions:</b> 8</p>	prolonged exposure (PE) therapy	40 minutes of PE: 5 minutes before rTMS, 30 minutes overlapping with rTMS, and continuing 5 minutes after rTMS	<p>HDRS</p> <p>[active rTMS + PE] vs [sham rTMS + PE]: <math>g=-1.093</math> (SE=0.691), ↑</p> <p>[active rTMS + PE]: ↑*</p>
Isserles et al., 2011 (43)	<p><b>Diagnosis:</b> non-psychotic MDD (n.m.), TRD</p> <p><b>[positive + rTMS] n:</b> 14 (7/7) <b>Age:</b> 45.93 ± 12.9</p> <p><b>[negative + rTMS] n:</b> 11 (6/5) <b>Age:</b> 41.75 ± 12.7</p> <p><b>[rTMS alone] n:</b> 20 (11/9) <b>Age:</b> 45.93 ± 12.98</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> 20 Hz</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> 1,680</p> <p><b>Total no. of rTMS sessions:</b> 20</p>	cognitive-emotional reactivation: positive, negative, or rTMS alone	Before & During rTMS	<p>HDRS</p> <p>[rTMS + positive] vs [rTMS alone]: <math>g=+0.425</math> (SE=0.344), n.s.</p> <p>[rTMS + negative] vs [rTMS alone]: <math>g=+0.805</math> (SE=0.344), n.s.</p> <p>[rTMS + positive]: <math>g=-1.594</math> (SE=0.392), ↑*</p> <p>[rTMS + negative]: <math>g=-1.317</math> (SE=0.395), ↑*</p>

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Kreuzer et al., 2012 (44)	<p><b>Diagnosis:</b> acute depressive episode (DSM-IV)</p> <p><b>[active rTMS + sleep deprivation] n:</b> 21 (10/11) <b>Age:</b> 45.3 ± 8.0</p> <p><b>[sham rTMS + sleep deprivation] n:</b> 16 (8/8) <b>Age:</b> 39.9 ± 13.3</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>rTMS parameters:</b> 10 Hz</p> <p><b>Intensity:</b> 110% RMT</p> <p><b>Pulses per session:</b> 1,000</p> <p><b>Total no. of rTMS sessions:</b> 4</p>	Sleep deprivation	Night before rTMS	<p>HDRS</p> <p>[active rTMS + sleep deprivation] vs [sham rTMS + sleep deprivation]: day 1: <math>g=-0.227</math> (SE=0.326), n.s. Day 2-4: n.s.</p> <p>[active rTMS + sleep deprivation]: day 1: <math>g=-2.226</math> (SE=0.402), ↑*</p>
Li et al., 2016 (45)	<p><b>Diagnosis:</b> MDD (n.m.)</p> <p><b>[active rTMS + active RECT] n:</b> 12 (4/8) <b>Age:</b> 43.4 ± 9.0</p> <p><b>[sham rTMS + active RECT] n:</b> 12 (6/6) <b>Age:</b> 42.4 ± 12.5</p> <p><b>[active rTMS + sham RECT]:</b> 12 (5/7) <b>Age:</b> 39.4 ± 13.2</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 100% MT</p> <p><b>Pulses per session:</b> 1,600</p> <p><b>Total no. of rTMS sessions:</b> 10</p>	computerized rACC-engaging cognitive task (RECT)	Immediately before rTMS	<p>HDRS</p> <p>[active rTMS + active RECT] vs [sham rTMS + active RECT]: <math>g=-1.247</math> (SE=0.433), ↑</p> <p>[active rTMS + active RECT] vs [active rTMS + sham RECT]: <math>g=-0.273</math> (SE=0.396), ↑</p> <p>[active rTMS + sham RECT] vs [sham rTMS + active RECT]: <math>g=-0.928</math> (SE=0.416), ↑</p> <p>[active rTMS + active RECT]: <math>g=-1.251</math> (SE=0.371), ↑*</p>



Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Mania & Kaur, 2019 (46)	<p><b>Patient Diagnosis (diagnostic method):</b> MDD (n.m.), TRD</p> <p><b>[rTMS + BLT] n:</b> 6 (n.m.) <b>Age:</b> n.m.</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> n.m.</p> <p><b>Intensity:</b> n.m.</p> <p><b>Pulses per session:</b> n.m.</p> <p><b>Total no. of rTMS sessions:</b> n.m.</p>	Bright Light Therapy (BLT)	During deep TMS	<p>HDRS</p> <p>[rTMS + BLT]: <math>g=-3.967</math> (SE=1.196), no statistical comparison reported</p>
Martinotti et al., 2022 (47)	<p><b>Diagnosis:</b> Cocaine Use Disorder (DSM-5)</p> <p><b>[active rTMS+ cue-induced craving] n:</b> 36 (31/5) <b>Age:</b> <math>35.8 \pm 8</math></p> <p><b>[sham rTMS + cue-induced craving] n:</b> 33 (29/4) <b>Age:</b> <math>37.9 \pm 6.6</math></p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> 15 Hz</p> <p><b>Intensity:</b> 100% RMT</p> <p><b>Pulses per session:</b> 2400</p> <p><b>Total no. of rTMS sessions:</b> 20</p>	cue-induced craving and suppression	During the first 2 minutes of each rTMS session.	<p>MADRS</p> <p>[active rTMS+ cue-induced craving] vs [sham rTMS + cue-induced craving]: <math>g=-0.585</math> (SE=0.255), <math>\uparrow</math></p> <p>[Active rTMS+ cue-induced craving]: <math>g=-1.029</math> (SE=0.203), <math>\uparrow^*</math></p>

Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Neacsiu et al., 2018 (48)	<p><b>Diagnosis:</b> MDD (MINI 6.0), TRD</p> <p><b>[rTMS + self-system therapy] n:</b> 5 (3/2) <b>Age:</b> 53.8 ± 4.32</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> 3,000</p> <p><b>Total no. of rTMS sessions:</b> 20</p>	self-system therapy	From the start of rTMS until after rTMS for approximately 2.5 mins.	<p>HDRS</p> <p>[rTMS + self-system therapy]: g=-2.490 (SE=0.865), ↑*</p>
Osuch et al., 2009 (49)	<p><b>Diagnosis:</b> PTSD (n.m.), MDD</p> <p><b>[active rTMS + exposure] n:</b> 9 (1/8) <b>Age:</b> 41.4 ± 12.3</p>	<p><b>Target site:</b> right DLPFC</p> <p><b>Frequency:</b> 1Hz</p> <p><b>Intensity:</b> 100% MT</p> <p><b>Pulses per session:</b> 1,800</p> <p><b>Total no. of rTMS sessions:</b> 20</p>	imaginal exposure therapy	During rTMS	<p>HDRS</p> <p>[active rTMS + exposure] vs [sham rTMS + exposure]: g=+0.435 (SE=1.063), n.s.</p> <p>[Active rTMS + exposure]: g=+0.470 (SE=1.142), n.s.*</p>
Ross et al., 2023 (50)	<p><b>Diagnosis:</b> post-stroke depression (DSM-IV)</p> <p><b>[active rTMS + aerobic exercise] n:</b> 6 (3/3) <b>Age:</b> 62.3 ± 12.5</p> <p><b>[rTMS alone] n:</b> 6 (2/4) <b>Age:</b> 58.3 ± 12.5</p> <p><b>[aerobic exercise alone] n:</b> 4 (1/3) <b>Age:</b> 51.5 ± 18.4</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> 5000</p> <p><b>Total no. of rTMS sessions:</b> 24</p>	aerobic exercise	Aerobic exercises occurred within 30 minutes before or after rTMS sessions	<p>PHQ-9</p> <p>[active rTMS + aerobic exercise]: g=-0.859 (SE=1.269), ↑*</p> <p>[active rTMS + aerobic exercise] vs. [rTMS alone]: g=+0.683 (SE=0.594)</p> <p>[active rTMS + aerobic exercise] vs. [aerobic exercise alone]: g=-0.578 (SE=0.658)</p>

Study	Sample Information	rTMS Protocol		Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
Russo et al., 2018 (51)	<p><b>Diagnosis:</b> MDD (n.m.), TRD</p> <p><b>[rTMS + behavioural activation] n:</b> 11 (0/11)</p> <p><b>Age:</b> 50 ± 18.9</p>	<p><b>Target site:</b> left DLPFC.</p> <p><b>Frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% MT</p> <p><b>Pulses per session:</b> 3000</p> <p><b>Total no. of rTMS sessions:</b> mean (SD): 33.0 ± 5.7</p>		behavioural activation	Goal attainment before rTMS; encouraged goal planning during stimulation; selection of the next goal after rTMS.	<p>IDS-SR</p> <p>[rTMS + behavioural activation]: g=-1.957 (SE=0.501), ↑*</p>
Thierree et al., 2022 (52)	<p><b>Diagnosis:</b> PTSD (DSM-IV)</p> <p><b>[HF rTMS + trauma script exposure] n:</b> 18 (5/13)</p> <p><b>Age:</b> 31.3 ± 10.0</p> <p><b>[LF rTMS + trauma script exposure] n:</b> 20 (8/12)</p> <p><b>Age:</b> 33.5 ± 11.1</p>	<p><b>rTMS parameters:</b> 10 Hz</p> <p><b>Intensity:</b> 110% RMT</p>	<p><b>Target site:</b> right DLPFC</p> <p><b>Pulses per session:</b> 3,000</p>	Trauma script exposure	During rTMS	<p>HDRS</p> <p>[HF rTMS + trauma script exposure]: g=-1.190 (SE=0.300), ↑*</p> <p>[LF rTMS + trauma script exposure]: g=-0.593 (SE=0.234), ↑*</p> <p>HF vs LF: n.s.</p>
<p><b>rTMS parameters:</b> 1 Hz</p> <p><b>Intensity:</b> 70% RMT</p>		<p><b>Total no. of rTMS sessions:</b> 8</p>				


Study	Sample Information	rTMS Protocol	Psychological Task or Intervention	Timing of Treatments	Assessment and Comparison Outcomes
VanDerwerker et al., 2018 (53)	<p><b>Diagnosis:</b> post-stroke depression (DSM-IV)</p> <p><b>[active rTMS + aerobic exercise] n:</b> 3 (2/1)</p> <p><b>Age:</b> 68.0 ± 12.5</p>	<p><b>Target site:</b> left DLPFC</p> <p><b>frequency:</b> 10 Hz</p> <p><b>Intensity:</b> 120% RMT</p> <p><b>Pulses per session:</b> 5000</p> <p><b>Total no. of rTMS sessions:</b> 24</p>	aerobic exercise	Aerobic exercise occurred within 30 minutes before or after rTMS sessions	<p>PHQ-9</p> <p>[active rTMS + aerobic exercise]: g=-1.508 (SE=0.594), no statistical comparison reported</p>
Vedeniapin et al., 2010 (54)	<p><b>Diagnosis:</b> MDD (n.m.), TRD</p> <p><b>[rTMS + CBT] n:</b> 1 (0/1)</p> <p><b>Age:</b> 26</p>	<p><b>Target site:</b> left PFC</p> <p><b>rTMS parameters:</b> 10 Hz</p> <p><b>Intensity:</b> 120% MT</p> <p><b>Pulses per session:</b> 6,000</p> <p><b>Total no. of rTMS sessions:</b> 39</p>	CBT	CBT delivered in 14/39 rTMS sessions, starting right before rTMS and continuing to during rTMS	<p>BDI</p> <p>Patient remitted</p>

↑: Significantly higher efficacy in experimental group [active rTMS + active adjunct] than control group (either sham or active comparator); ↑\*: Significant improvement within experimental group; ↓: Significantly lower efficacy in experimental group than control group; >: Significant higher efficacy in [active positive adjunct] than [active negative adjunct]; Hedges' g is computed from change scores between baseline and immediate assessment after the end of rTMS treatment course; AD: Alzheimer's disease; BD: Bipolar disorder; BDI: Beck Depression Inventory; CBT: Cognitive Behavioral Therapy; DSM: Diagnostic and Statistical Manual of Mental Disorders; HDRS: Hamilton Depression Rating Scale; HF: high frequency; IDS-SR: Inventory for Depressive Symptomatology (Self-Report); DLPFC: dorsolateral prefrontal cortex; LF: low frequency; L-pSAC: Left-parietal somatosensory association cortex; MADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; MINI: Mini International Neuropsychiatric Interview; n: Sample size; n.m.: Not mentioned; n.s.: non-significant changed or difference between groups comparison; n.s.\*: non-significantly change or difference within groups comparison; PHQ-9: Patient Health Questionnaire-9; PTSD: post-traumatic stress disorder; R-pSAC: right-parietal somatosensory association cortex; SD: Standard deviation; SE: standard error; TRD: treatment-resistant depression.

### *Meta-analysis results of depression change scores across disorders*

The number of included studies allowed for three meta-analyses (of four discussed in *Groups and Comparisons* section above): within-group comparisons of [active rTMS + active PSYC], or endpoint minus baseline scores; between group comparisons of [active rTMS + active PSYC] versus [active rTMS + sham PSYC]; and between-group comparisons of [active rTMS + active PSYC] versus [sham rTMS + active PSYC].

Seventeen studies (20 datasets) reported endpoint versus baseline changes for an [active rTMS + active PSYC] treatment. This uncontrolled effect on depression severity across disorders was large and significantly therapeutic with a corrected standardized mean difference (g) of -1.91, (standard error (SE) = 0.45, 95% confidence interval (CI) = -2.80 to -1.03),  $p < 0.01$ ). However, these results were substantially heterogeneous ( $Q(df=19) = 126.59$ ,  $p < 0.01$ ,  $I^2 = 97.27\%$ ). Meta-regression results suggest age and sex ratio are non-significant moderators ( $p > 0.05$ ), but whether PSYC was an antidepressant intervention was significant (coefficient = -1.745, SE = 0.819, 95% CI = -3.350 to -0.140,  $p = 0.0331$ ). This significant negative moderation indicates that depression severity decreases further when rTMS is combined with an intervention for depression. Leave-one-out sensitivity tests indicated a robust meta-analytic estimate, with g ranging between -2.01 to -1.41 ( $p < 0.01$  for each iteration). Publication bias may possibly be an issue: despite Egger's test being non-significant, the funnel plot appears asymmetric with bias towards lower efficacy (**Figure 3a**).



**Figure 3.** (a) Pooled within-group comparisons (endpoint - baseline) of [active rTMS + active PSYC] treatment. (b) Between-group comparisons of change scores between [active rTMS + active PSYC] and [sham rTMS + active PSYC] groups. Black box sizes indicate weight in the pooled estimate.

Eight studies compared [active rTMS + active PSYC] versus [sham rTMS + active PSYC]. This controlled effect on depression severity across disorders was medium and significantly therapeutic with  $g$  of  $-0.55$  ( $SE = 0.14$ ,  $95\% CI = -0.82$  to  $-0.28$ ,  $p < 0.01$ ). These results were not heterogeneous ( $Q(df=7)=5.84$ ,  $p=0.56$ ,  $I^2 = 0.00\%$ ). Leave-one-out sensitivity tests indicated a robust meta-analytic estimate, with  $g$  ranging between  $-0.62$  to  $-0.47$  ( $p < 0.01$  for each iteration). Publication bias did not appear to be an issue as the funnel plot appears symmetric (**Figure 3b**).

Four studies compared groups receiving [active rTMS + active PSYC] versus [active rTMS + sham PSYC]. This controlled effect on depression severity was not significant. Pooled study effects were substantially heterogeneous ( $Q(df=3)=46.00$ ,  $p<0.01$ ,  $I^2 = 90.22\%$ ). Leave-one-out sensitivity tests indicated a poor reliability of the estimate, with  $g$  ranging between  $-0.32$  to  $+0.44$  (each iteration remained non-significant). The funnel plot appeared symmetric, indicating unlikely publication bias (**Supplementary Text 2**).


### Secondary meta-analysis: left DLPFC treatment for depressive disorders

The above meta-analyses were repeated but only including studies that targeted the left DLPFC to treat patients with depressive disorders (e.g., MDD or post-stroke depression). Forest and funnel plots are provided in **Supplementary Text 3**. Meta-analytic estimates are shown in **Figure 4**.

Within-group comparisons of [active rTMS + active PSYC] at endpoint minus baseline change scores included 14 studies (16 datasets), with a large and significantly therapeutic  $g$  of  $-2.23$ , ( $SE = 0.60$ ,  $95\% CI = -3.41$  to  $-1.05$ ),  $p < 0.01$ ), albeit with substantial heterogeneity ( $Q(df=15) = 111.21$ ,  $p < 0.01$ ,  $I^2 = 97.74\%$ ). Mixed findings for publication bias were observed: Egger's test was not significant, but the funnel plot was asymmetric. Leave-one-out sensitivity tests suggested robust findings ( $g$ -range =  $-2.39$  to  $-1.59$ ,  $p < 0.01$  for each iteration). Age, sex ratio, and whether PSYC was an antidepressant therapy were non-significant moderators.

Five studies compared [active rTMS + active PSYC] versus [sham rTMS + active PSYC] and targeted the left DLPFC of patients with depressive conditions. The effect was medium and significantly therapeutic with  $g$  of  $-0.52$  ( $SE = 0.18$ ,  $95\%CI = -0.87$  to  $-0.18$ ,  $p < 0.01$ ). The results were not heterogenous ( $Q(df=4)=4.31$ ,  $p=0.36$ ,  $I^2 = 4.11\%$ ). However, leave-one-out sensitivity tests indicated an unstable meta-analytic estimate, with  $g$  ranging from  $-0.64$  to  $-0.39$ , (only non-significant when Duan et al. (40) was excluded). Publication bias may not be an issue as the funnel plot appeared symmetric.

The four studies that compared [active rTMS + active PSYC] versus [active rTMS + sham PSYC] groups all applied rTMS to the left DLPFC of patients with depressive disorders.



**Figure 4.** Meta-analytic estimates of studies treating patients with depressive disorders and targeting the left dorsolateral prefrontal cortex (DLPFC). Blue bars are based on findings in this review; the red bar is based on findings from Kan et al., *Lancet Psychiatry* (3). <sup>0</sup>Estimate is based on 14 uncontrolled studies (16 datasets); <sup>1</sup>estimate is based on five controlled trials; <sup>2</sup>estimate is based on four controlled trials; <sup>3</sup>estimate is based on 61 controlled trials. \* Pooled estimate was statistically significant ( $p < 0.01$ ).

### *Power analysis results*

Power analysis curves are included in the **Supplementary Text 4**. Average change scores reported by Li et al. (45) were imputed for the following groups: [active rTMS + active PSYC], [active rTMS + sham PSYC], and [sham rTMS + active PSYC]. Li et al.'s study was selected as these authors included two active comparators and their findings supported the hypothesis that combining rTMS with PSYC improved antidepressant efficacy over either alone. However, Li et al. did not include a [sham rTMS + sham PSYC] group; we imputed average change scores for this group from Duan et al. (40), as these authors used the same standardized assessment (17-item Hamilton Depression Rating Scale), treated patients diagnosed with MDD, and combined sham rTMS with a control for active PSYC.

To test the hypothesis that [active rTMS + active PSYC] is significantly better than [sham rTMS + active PSYC] and [sham rTMS + sham PSYC], but not compared to [active rTMS + sham PSYC], a clinical trial with four independent groups would need to recruit 80 patients (20 patients per group). For the hypothesis that both active treatment is better than all active and sham comparators (including [active rTMS + sham PSYC]), the number of patients needed jumps to 240 (60 patients per group). This increased sample size requirement for sufficient power is due to the small difference in average change scores between the [active rTMS + active PSYC] and [active rTMS + sham PSYC] groups. Given these findings, only two included studies (35, 40) were sufficiently powered.



## Discussion

Following PRISMA-ScR guidelines (29), this scoping review and meta-analysis chartered the literature on the antidepressant efficacy of combining rTMS with psychological tasks or interventions. As of 10 July 2024, this literature comprised twenty studies, **Table 1**; (35-54), combining rTMS with psychotherapy, bright light therapy, aerobic exercise, partial and total sleep deprivation, cognitive training, cognitive emotional reactivation, and a psychophysical task.

Numerous systematic reviews and meta-analyses have investigated the antidepressant efficacy of pharmacological, psychological, and non-invasive brain stimulation therapies. For example, an umbrella review of meta-analyses found a small yet significant effect size when pharmacological or psychological treatments are used independently (55). The efficacy of rTMS alone also shows promise, with a meta-analysis of various rTMS protocols indicating small to medium effect sizes on depressive conditions (2). In contrast, a cross-diagnostic meta-analysis focusing on protocols targeting the left DLPFC found a medium to large effect size for depressive symptoms across neuropsychiatric conditions (3).

There is increasing interest in identifying synergies between treatments to advance these approaches. For instance, Rakesh et al. (56) recently conducted a meta-analysis on the synergistic effects of rTMS with pharmacological treatments, observing a large effect size of rTMS with antidepressants compared to sham rTMS with antidepressant. This scoping review contributes to the field by providing meta-analytic estimates of the efficacy of combining rTMS with psychological tasks and interventions. Results suggest that while the antidepressant efficacy of combining rTMS with psychological methods is promising, it does not surpass the efficacy of rTMS alone.

### *Uncontrolled meta-analysis results*

Uncontrolled clinical trials show a large, significant, and robust short-term reduction of depressive symptom severity, measured by comparing treatment endpoint to baseline scores. However, these results are substantially heterogeneous, and publication bias is possible. The meta-analysis findings remain consistent even when limited to studies targeting the left DLPFC for treating depressive conditions, such as MDD, post-stroke depression, or comorbid MDD with PTSD or dysthymia. Meta-regressions showed that age and sex were not significant moderators for both pooled estimates. However, whether the concurrent psychological method treated depressive symptoms was a significant moderator for the pooled estimate across protocols and diagnoses (**Figure 3a**), but not significant when focusing on left DLPFC protocols for patients with depressive conditions (**Supplementary Text 3**). The difference may be due to highly mixed outcomes, as pooled estimates showed significant and substantial heterogeneity. Additionally, the notably high efficacy of left DLPFC protocols for depressive symptoms may also overshadow the antidepressant effects of psychological augmentations – a recent cross-diagnostic meta-analysis of 61 clinical trials observed a Hedge's  $g$  of 0.959 (95%CI=-1.209 to -0.708) with rTMS alone compared to sham rTMS alone (3). While the large effect sizes from the uncontrolled meta-analysis show promise and support further investigations, the estimates are uncontrolled and exhibit substantial heterogeneity.

### *Controlled meta-analysis results*

Control groups are essential baselines for distinguishing combination treatment effects from confounding variables like placebo effects and natural symptom fluctuations in episodic conditions such as depression. Additionally, to draw causal conclusions about synergistic, antagonistic, or null effects of psychological method combinations with rTMS, antidepressant outcomes must be compared with rTMS alone and psychological methods alone. For example, if combining rTMS with a psychological interventions result in a moderate effect size, but rTMS alone produces a large effect, the outcome might be misinterpreted as synergistic when it is actually antagonistic. Such antagonistic effects may explain findings by Isserles et al. (43). An additional concern for rTMS is that its antidepressant effects are substantially heterogeneous (3-5), making drawing conclusions from uncontrolled observations highly problematic. However, there are challenges with a control condition for psychological interventions, such that few studies could have included sham conditions.

Given these challenges, it was possible to pool study findings for two types of comparisons. In the first comparison, pooling results from seven studies, the active combination treatment [active rTMS + active PSYC] was significantly more effective than [sham rTMS + active PSYC], with a medium effect size. This robust meta-analytic estimate was consistent and supported by a funnel plot indicating no publication bias. In the second comparison, pooling results from three studies, the effect size for [active rTMS + active PSYC] versus [active rTMS + sham PSYC] was non-significant and highly heterogeneous. These results suggest that combining psychological methods with rTMS enhances efficacy, but the reverse effect is not supported. Although it must be emphasized that the number of pooled studies was small for both comparisons, e.g., multiple analyses requiring more than ten pooled studies not recommended.

The results of various meta-analytic estimates are summarized in **Figure 3a** and highlighted by a power analysis (**Supplementary Text 4**). The meta-analytic effect size of active rTMS compared to sham rTMS in patients with depressive conditions is significantly large, though notably heterogeneous (3). Relative to this effect size, the benefits of including a psychological task or intervention to enhance the efficacy of rTMS is not supported. The simulations-based power analysis highlights this difference in effect size. Using the observed effect sizes of [active rTMS + active PSYC] versus rTMS alone, and assuming significant superiority of combination over rTMS alone, the number of patients needed to obtain sufficient power is 80 patients per group (240 total). Compared with 20 patients per group (80 total) if simply testing the hypothesis that the combination treatment is better than sham or the psychological method alone.

### *Notable observations from included studies*

Bright light therapy with rTMS is the most promising combination therapy for depression. Two controlled studies reported encouraging outcomes: a large effect size indicated superior efficacy when bright light therapy was administered on mornings of rTMS treatment days and compared to rTMS alone (35); and a separate research team observed large reductions of HDRS scores in six patients with treatment resistant depression when bright light therapy was administered during rTMS sessions (46).

This scoping review was motivated by concerns that brain states may influence the antidepressant effects of rTMS. Two identified studies illustrate these concerns through

controlled designs. During rTMS, Isserless et al. (43) guided patients towards negative or positive thinking during rTMS, operationalized as thoughts that mitigate or exacerbate depressive symptoms. Treatment outcomes for these groups were compared to patients receiving rTMS alone. Assessed using Beck's Depression Index, the authors identified a significant antagonistic effect by the negative thinking condition. These findings need to be replicated as the sample size was small, the finding was not observed when assessing symptom severity with the HDRS, and the design of Isserles et al. (43) may not dissociate whether negative thinking blocked the effects of rTMS (a 'brain state' effect) or reinforced depressive symptoms. Nevertheless, the authors cautioned the need to control for brain state during antidepressant protocols of rTMS (43). In contrast, Li et al. (45) had patients complete a shape-discrimination task just before high frequency rTMS, as this task was observed to induce frontal electroencephalogram theta activity (57), which persisted after the completion of the psychological task (45). This combination significantly boosted antidepressant effects compared to [active rTMS + sham PSYC] (with a small effect size; **Table 2**).

## Limitations

Our screening protocol by title and abstract may have missed studies if these details were only provided in the main text and not the title or abstract; or if they were not discussed in relevant reviews (24-27) or not in the reference list of fully screened studies. Meta-analyses for controlled studies were also based on a small number of studies, restricting our analysis to pooled statistics and funnel plots only; Egger's tests or meta-regressions when study count was below ten were not conducted due to limited power of such analyses.

## Conclusion

Notwithstanding the low number of studies, when comparing the meta-analytic findings of combined treatments (**Figure 4**) with literature on rTMS alone (2, 3), where patients are typically instructed to relax during sessions, rTMS shows promise as an augmentation for psychological interventions. However, for rTMS alone, simply instructing patients to relax seems sufficient for effective antidepressant protocols.

**Author contributions.** Conceptualization and funding, CGG, GSK; literature screening, CGG, YTC, HYCC, SWC, YYC, AHPT, MJ; chartering table, CGG; data extraction, CGG; extracted data verification, MX and AHPT; data analysis, CGG; data interpretation, CGG and GSK; writing first draft, CGG; revisions to draft, AHPT, MJ, GSK.

**Acknowledgements.** We would like to thank our former students for assisting in the initial literature screening: Yuet Tung Chan (YTC), Chui Yee Cheung (CYC), Hoi Yan Clarice Cheuk (HYCC), Sze Wing Cheung, (SWC) and Ying Yau Choi (YYC).

**Financial support.** This work was supported by the General Research Fund under the University Grants Committee of the Hong Kong Special Administrative Region (numbers 15100120, 25100219 and 15106222) and the Mental Health Research Center, The Hong Kong Polytechnic University.

**Conflict of interest.** None.

## References

1. Lefaucheur JP, Aleman A, Baeken C, Benninger DH, Brunelin J, Di Lazzaro V, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). *Clin Neurophysiol.* 2020;131(2):474-528.
2. Hyde J, Carr H, Kelley N, Seneviratne R, Reed C, Parlatini V, et al. Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials. *Mol Psychiatry.* 2022;27(6):2709-19.
3. Kan RLD, Padberg F, Giron CG, Lin TTZ, Zhang BBB, Brunoni AR, Kranz GS. Effects of repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex on symptom domains in neuropsychiatric disorders: a systematic review and cross-diagnostic meta-analysis. *Lancet Psychiatry.* 2023;10(4):252-9.
4. Klooster DCW, Ferguson MA, Boon P, Baeken C. Personalizing Repetitive Transcranial Magnetic Stimulation Parameters for Depression Treatment Using Multimodal Neuroimaging. *Biol Psychiatry Cogn Neurosci Neuroimaging.* 2022;7(6):536-45.
5. Padberg F, Bulubas L, Mizutani-Tiebel Y, Burkhardt G, Kranz GS, Koutsouleris N, et al. The intervention, the patient and the illness - Personalizing non-invasive brain stimulation in psychiatry. *Exp Neurol.* 2021;341:113713.
6. Hebel T, Grozinger M, Landgrebe M, Padberg F, Schecklmann M, Schlaepfer T, et al. Evidence and expert consensus based German guidelines for the use of repetitive transcranial magnetic stimulation in depression. *World J Biol Psychiatry.* 2022;23(5):327-48.
7. Bulteau S, Laurin A, Pere M, Fayet G, Thomas-Ollivier V, Deschamps T, et al. Intermittent theta burst stimulation (iTBS) versus 10 Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) to alleviate treatment-resistant unipolar depression: A randomized controlled trial (THETA-DEP). *Brain Stimul.* 2022;15(3):870-80.
8. Disner SG, Beevers CG, Haigh EA, Beck AT. Neural mechanisms of the cognitive model of depression. *Nat Rev Neurosci.* 2011;12(8):467-77.
9. Goldstein-Piekarski AN, Ball TM, Samara Z, Staveland BR, Keller AS, Fleming SL, et al. Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety. *Biol Psychiatry.* 2022;91(6):561-71.
10. Schutter D, Smits F, Klaus J. Mind matters: A narrative review on affective state-dependency in non-invasive brain stimulation. *Int J Clin Health Psychol.* 2023;23(3):100378.
11. Sack AT, Paneva J, Kuthe T, Dijkstra E, Zwienerberg L, Arns M, Schuhmann T. Target Engagement and Brain State Dependence of Transcranial Magnetic Stimulation: Implications for Clinical Practice. *Biol Psychiatry.* 2024;95(6):536-44.
12. Silvanto J, Muggleton N, Walsh V. State-dependency in brain stimulation studies of perception and cognition. *Trends Cogn Sci.* 2008;12(12):447-54.
13. Xia AWL, Jin M, Qin PPI, Kan RLD, Zhang BBB, Giron CG, et al. Instantaneous effects of prefrontal transcranial magnetic stimulation on brain oxygenation: A systematic review. *Neuroimage.* 2024;293:120618.
14. Silvanto J, Pascual-Leone A. State-dependency of transcranial magnetic stimulation. *Brain Topogr.* 2008;21(1):1-10.

15. Bestmann S, Swayne O, Blankenburg F, Ruff CC, Haggard P, Weiskopf N, et al. Dorsal premotor cortex exerts state-dependent causal influences on activity in contralateral primary motor and dorsal premotor cortex. *Cereb Cortex*. 2008;18(6):1281-91.
16. Huang YZ, Rothwell JC, Edwards MJ, Chen RS. Effect of physiological activity on an NMDA-dependent form of cortical plasticity in human. *Cereb Cortex*. 2008;18(3):563-70.
17. Luber B, Balsam P, Nguyen T, Gross M, Lisanby SH. Classical conditioned learning using transcranial magnetic stimulation. *Exp Brain Res*. 2007;183(3):361-9.
18. Grosshagauer S, Woletz M, Vasileiadi M, Linhardt D, Nohava L, Schuler AL, et al. Chronometric TMS-fMRI of personalized left dorsolateral prefrontal target reveals state-dependency of subgenual anterior cingulate cortex effects. *Mol Psychiatry*. 2024.
19. Hoy KE, Enticott PG, Daskalakis ZJ, Fitzgerald PB. Can a behavioral intervention enhance the effect of repetitive transcranial magnetic stimulation on mood? *Brain Stimul*. 2010;3(4):200-6.
20. Bakulin I, Zabirova A, Lagoda D, Poydasheva A, Cherkasova A, Pavlov N, et al. Combining HF rTMS over the Left DLPFC with Concurrent Cognitive Activity for the Offline Modulation of Working Memory in Healthy Volunteers: A Proof-of-Concept Study. *Brain Sci*. 2020;10(2).
21. Dalhuisen I, Schutte C, Bramson B, Roelofs K, van Eijndhoven P, Tendolkar I. Studying additive effects of combining rTMS with cognitive control training: a pilot investigation. *Front Hum Neurosci*. 2023;17:1201344.
22. Remue J, Baeken C, De Raedt R. Does a single neurostimulation session really affect mood in healthy individuals? A systematic review. *Neuropsychologia*. 2016;85:184-98.
23. Xu M, Nikolin S, Samaratunga N, Chow EJH, Loo CK, Martin DM. Cognitive Effects Following Offline High-Frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) in Healthy Populations: A Systematic Review and Meta-Analysis. *Neuropsychol Rev*. 2024;34(1):250-76.
24. Sathappan AV, Luber BM, Lisanby SH. The Dynamic Duo: Combining noninvasive brain stimulation with cognitive interventions. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;89:347-60.
25. Tatti E, Phillips AL, Paciorek R, Romanella SM, Dettore D, Di Lorenzo G, et al. Boosting psychological change: Combining non-invasive brain stimulation with psychotherapy. *Neurosci Biobehav Rev*. 2022;142:104867.
26. Tsagaris KZ, Labar DR, Edwards DJ. A Framework for Combining rTMS with Behavioral Therapy. *Front Syst Neurosci*. 2016;10:82.
27. Wilkinson ST, Holtzheimer PE, Gao S, Kirwin DS, Price RB. Leveraging Neuroplasticity to Enhance Adaptive Learning: The Potential for Synergistic Somatic-Behavioral Treatment Combinations to Improve Clinical Outcomes in Depression. *Biol Psychiatry*. 2019;85(6):454-65.
28. Kochanowski B, Kageki-Bonnert K, Pinkerton EA, Dougherty DD, Chou T. A Review of Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation Combined with Medication and Psychotherapy for Depression. *Harv Rev Psychiatry*. 2024;32(3):77-95.
29. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018;169(7):467-73.

30. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. *Cochrane Handbook for Systematic Reviews of Interventions*. 2 ed: The Cochrane Collaboration and John Wiley & Sons Ltd.; 2019.
31. Hedges LV. Distribution Theory for Glass's Estimator of Effect size and Related Estimators. *Journal of Educational Statistics*. 1981;6(2):107-28.
32. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical Software*. 2010;36(3).
33. R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing. 2024.
34. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002.
35. Barbini B, Attanasio F, Manfredi E, Cavallini MC, Zanardi R, Colombo C. Bright light therapy accelerates the antidepressant effect of repetitive transcranial magnetic stimulation in treatment resistant depression: a pilot study. *Int J Psychiatry Clin Pract*. 2021;25(4):375-7.
36. Bentwich J, Dobronevsky E, Aichenbaum S, Shorer R, Peretz R, Khaigrekht M, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study. *J Neural Transm (Vienna)*. 2011;118(3):463-71.
37. Caloc'h T, Le Saout E, Litaneur S, Suarez A, Durand S, Lefaucheur JP, Nguyen JP. Treatment of cognitive and mood disorders secondary to traumatic brain injury by the association of bilateral occipital nerve stimulation and a combined protocol of multisite repetitive transcranial magnetic stimulation and cognitive training: A case report. *Front Neurol*. 2023;14:1195513.
38. Cavallero F, Gold MC, Tirrell E, Kokdere F, Donachie N, Steinfink D, et al. Audio-Guided Mindfulness Meditation During Transcranial Magnetic Stimulation Sessions for the Treatment of Major Depressive Disorder: A Pilot Feasibility Study. *Front Psychol*. 2021;12:678911.
39. Donse L, Padberg F, Sack AT, Rush AJ, Arns M. Simultaneous rTMS and psychotherapy in major depressive disorder: Clinical outcomes and predictors from a large naturalistic study. *Brain Stimul*. 2018;11(2):337-45.
40. Duan H, Yan X, Meng S, Qiu L, Zhang J, Yang C, Liu S. Effectiveness Evaluation of Repetitive Transcranial Magnetic Stimulation Therapy Combined with Mindfulness-Based Stress Reduction for People with Post-Stroke Depression: A Randomized Controlled Trial. *Int J Environ Res Public Health*. 2023;20(2).
41. Eichhammer P, Kharraz A, Wiegand R, Langguth B, Frick U, Aigner JM, Hajak G. Sleep deprivation in depression stabilizing antidepressant effects by repetitive transcranial magnetic stimulation. *Life Sci*. 2002;70(15):1741-9.
42. Fryml LD, Pelic CG, Acierno R, Tuerk P, Yoder M, Borckardt JJ, et al. Exposure Therapy and Simultaneous Repetitive Transcranial Magnetic Stimulation: A Controlled Pilot Trial for the Treatment of Posttraumatic Stress Disorder. *J ECT*. 2019;35(1):53-60.
43. Isserles M, Rosenberg O, Dannon P, Levkovitz Y, Kotler M, Deutsch F, et al. Cognitive-emotional reactivation during deep transcranial magnetic stimulation over the prefrontal cortex of depressive patients affects antidepressant outcome. *J Affect Disord*. 2011;128(3):235-42.

44. Kreuzer PM, Langguth B, Schecklmann M, Eichhammer P, Hajak G, Landgrebe M. Can repetitive transcranial magnetic stimulation prolong the antidepressant effects of sleep deprivation? *Brain Stimul.* 2012;5(2):141-7.
45. Li CT, Hsieh JC, Huang HH, Chen MH, Juan CH, Tu PC, et al. Cognition-Modulated Frontal Activity in Prediction and Augmentation of Antidepressant Efficacy: A Randomized Controlled Pilot Study. *Cereb Cortex.* 2016;26(1):202-10.
46. Mania I, Kaur J. Bright Light Therapy and rTMS; novel combination approach for the treatment of depression. *Brain Stimul.* 2019;12(5):1338-9.
47. Martinotti G, Pettoruso M, Montemiro C, Spagnolo PA, Acuti Martellucci C, Di Carlo F, et al. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry.* 2022;116:110513.
48. Neacsiu AD, Luber BM, Davis SW, Bernhardt E, Strauman TJ, Lisanby SH. On the Concurrent Use of Self-System Therapy and Functional Magnetic Resonance Imaging-Guided Transcranial Magnetic Stimulation as Treatment for Depression. *J ECT.* 2018;34(4):266-73.
49. Osuch EA, Benson BE, Luckenbaugh DA, Geraci M, Post RM, McCann U. Repetitive TMS combined with exposure therapy for PTSD: a preliminary study. *J Anxiety Disord.* 2009;23(1):54-9.
50. Ross RE, VanDerwerker CJ, George MS, Gregory CM. Feasibility of performing a multi-arm clinical trial examining the novel combination of repetitive transcranial magnetic stimulation and aerobic exercise for post-stroke depression. *Top Stroke Rehabil.* 2023;30(7):649-62.
51. Russo GB, Tirrell E, Busch A, Carpenter LL. Behavioral activation therapy during transcranial magnetic stimulation for major depressive disorder. *J Affect Disord.* 2018;236:101-4.
52. Thierree S, Raulin-Briot M, Legrand M, Le Gouge A, Vancappel A, Tudorache AC, et al. Combining Trauma Script Exposure With rTMS to Reduce Symptoms of Post-Traumatic Stress Disorder: Randomized Controlled Trial. *Neuromodulation.* 2022;25(4):549-57.
53. VanDerwerker CJ, Ross RE, Stimpson KH, Embry AE, Aaron SE, Cence B, et al. Combining therapeutic approaches: rTMS and aerobic exercise in post-stroke depression: a case series. *Top Stroke Rehabil.* 2018;25(1):61-7.
54. Vedeniapin A, Cheng L, George MS. Feasibility of simultaneous cognitive behavioral therapy and left prefrontal rTMS for treatment resistant depression. *Brain Stimul.* 2010;3(4):207-10.
55. Leichsenring F, Steinert C, Rabung S, Ioannidis JPA. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. *World Psychiatry.* 2022;21(1):133-45.
56. Rakesh G, Cordero P, Khanal R, Himelhoch SS, Rush CR. Optimally combining transcranial magnetic stimulation with antidepressants in major depressive disorder: A systematic review and Meta-analysis. *J Affect Disord.* 2024;358:432-9.
57. Min BK, Park HJ. Task-related modulation of anterior theta and posterior alpha EEG reflects top-down preparation. *BMC Neurosci.* 2010;11:79.